

## FDA-APPROVED BIOSIMILARS (Part 1 of 2)

An FDA-approved biosimilar is a biological product which demonstrates that it is highly similar to an already-approved biological product and has no clinically meaningful differences in terms of safety, purity and potency from the reference product, as well as meeting other criteria specified by law. An approved biosimilar is not interchangeable with its reference product, or with another biosimilar of the same reference product.

Biosimilar	Brand	Company	Dosage Form	Indication <sup>†</sup>
<b>REFERENCE PRODUCT: AVASTIN</b>				
bevacizumab-adcd	<b>Vegzelma*</b>	Celltrion	soln for IV infusion	<ul style="list-style-type: none"> <li>• Colorectal carcinoma</li> <li>• Non-squamous non-small cell lung cancer</li> <li>• Recurrent glioblastoma</li> <li>• Renal cell carcinoma</li> <li>• Cervical cancer</li> <li>• Epithelial ovarian, fallopian tube or primary peritoneal cancer</li> </ul>
bevacizumab-awwb	<b>Mvasi</b>	Amgen		
bevacizumab-bvzr	<b>Zirabev</b>	Pfizer		
bevacizumab-maly	<b>Alymlys</b>	Amneal		
<b>REFERENCE PRODUCT: ENBREL</b>				
etanercept-szsz	<b>Erelzi*</b>	Sandoz	soln for SC inj	<ul style="list-style-type: none"> <li>• Rheumatoid arthritis</li> <li>• Polyarticular juvenile idiopathic arthritis</li> <li>• Ankylosing spondylitis</li> </ul>
etanercept-ykro	<b>Eticovo*</b>	Merck	soln for SC inj	<ul style="list-style-type: none"> <li>• Rheumatoid arthritis</li> <li>• Polyarticular juvenile idiopathic arthritis</li> <li>• Psoriatic arthritis</li> <li>• Ankylosing spondylitis</li> <li>• Plaque psoriasis</li> </ul>
<b>REFERENCE PRODUCT: HERCEPTIN</b>				
trastuzumab-anns	<b>Kanjinti</b>	Amgen	pwd for IV infusion	<ul style="list-style-type: none"> <li>• Breast cancer</li> <li>• Gastric or gastroesophageal junction adenocarcinoma</li> </ul>
trastuzumab-dkst	<b>Ogivri</b>	Mylan		
trastuzumab-dttb	<b>Ontruzant</b>	Merck		
trastuzumab-pkrb	<b>Herzuma</b>	Celltrion and Teva		
trastuzumab-qyyp	<b>Trazimera</b>	Pfizer		
<b>REFERENCE PRODUCT: HUMIRA</b>				
adalimumab-adaz	<b>Hyrimoz*</b>	Sandoz	soln for SC inj	<ul style="list-style-type: none"> <li>• Rheumatoid arthritis</li> <li>• Juvenile idiopathic arthritis</li> <li>• Psoriatic arthritis</li> <li>• Ankylosing spondylitis</li> <li>• Crohn's disease</li> <li>• Ulcerative colitis</li> <li>• Plaque psoriasis</li> </ul>
adalimumab-adbm	<b>Cyltezo*</b>	Boehringer Ingelheim		
adalimumab-afzb	<b>Abilada*</b>	Pfizer		
adalimumab-atto	<b>Amjevita*</b>	Amgen		
adalimumab-aqvh	<b>Yusimry*</b>	Coherus		
adalimumab-bwwd	<b>Hadlima*</b>	Merck		
adalimumab-fkjp	<b>Hulio*</b>	Mylan		
<b>REFERENCE PRODUCT: LANTUS</b>				
insulin glargine-aglr	<b>Rezvoglar*</b>	Eli Lilly	soln for SC inj	<ul style="list-style-type: none"> <li>• Diabetes</li> </ul>
insulin glargine-yfgn	<b>Semglee</b>	Mylan		
<b>REFERENCE PRODUCT: LUCENTIS</b>				
ranibizumab	<b>Susvimo</b>	Genentech	intravitreal implant	<ul style="list-style-type: none"> <li>• Neovascular (wet) age-related macular degeneration</li> </ul>
ranibizumab-eqrn	<b>Cimerli</b>	Coherus	soln for oph intravitreal inj	<ul style="list-style-type: none"> <li>• Neovascular (wet) age-related macular degeneration</li> <li>• Macular edema following retinal vein occlusion</li> <li>• Diabetic macular edema</li> <li>• Diabetic retinopathy</li> <li>• Myopic choroidal neovascularization</li> </ul>
ranibizumab-nuna	<b>Byooviz</b>	Biogen	soln for oph intravitreal inj	<ul style="list-style-type: none"> <li>• Neovascular (wet) age-related macular degeneration</li> <li>• Macular edema following retinal vein occlusion</li> <li>• Myopic choroidal neovascularization</li> </ul>

(continued)

## FDA-APPROVED BIOSIMILARS (Part 2 of 2)

Biosimilar	Brand	Company	Dosage Form	Indication <sup>†</sup>
<b>REFERENCE PRODUCT: NEULASTA</b>				
pegfilgrastim-apgf	<b>Nyvepria</b>	Pfizer	soln for SC inj	<ul style="list-style-type: none"> <li>Decrease incidence of infection (febrile neutropenia) in patients on myelosuppressive chemotherapy</li> </ul>
pegfilgrastim-bmez	<b>Ziextenzo</b>	Sandoz		
pegfilgrastim-cbqv	<b>Udenyca</b>	Coherus Biosciences		
pegfilgrastim-jmdb	<b>Fulphila</b>	Mylan		
pegfilgrastim-pbbk	<b>Fylnetra*</b>	Amneal		
<b>REFERENCE PRODUCT: NEUPOGEN</b>				
filgrastim-aafi	<b>Nivestym</b>	Pfizer	soln for SC inj or IV infusion	<ul style="list-style-type: none"> <li>Decrease incidence of infection (febrile neutropenia) in patients on myelosuppressive chemotherapy</li> <li>Reduce time to neutrophil recovery and fever duration after induction/consolidation in AML</li> <li>Reduce duration and incidence of neutropenia</li> <li>Mobilization of hematopoietic progenitor cells</li> </ul>
filgrastim-ayow	<b>Releuko</b>	Amneal		
filgrastim-sndz	<b>Zarxio</b>	Sandoz		
<b>REFERENCE PRODUCT: PROCRIT OR EPOGEN</b>				
epoetin alfa-epbx	<b>Retacrit</b>	Pfizer	soln for IV or SC inj	<ul style="list-style-type: none"> <li>Anemia due to chronic kidney disease</li> <li>Anemia due to zidovudine in HIV</li> <li>Chemotherapy-induced anemia in patients with non-myeloid malignancies</li> <li>Reduction of allogeneic red blood cell transfusion in anemic patients undergoing surgery</li> </ul>
<b>REFERENCE PRODUCT: REMICADE</b>				
infliximab-abda	<b>Renflexis</b>	Merck	pwd for IV infusion	<ul style="list-style-type: none"> <li>Rheumatoid arthritis</li> <li>Psoriatic arthritis</li> <li>Ankylosing spondylitis</li> <li>Crohn's disease</li> <li>Ulcerative colitis</li> <li>Plaque psoriasis</li> </ul>
infliximab-axxq	<b>Avsola</b>	Amgen		
infliximab-dyyb	<b>Inflectra</b>	Pfizer		
<b>REFERENCE PRODUCT: RITUXAN</b>				
rituximab-abbs	<b>Truxima</b>	Celltrion and Teva	soln for IV infusion	<ul style="list-style-type: none"> <li>Rheumatoid arthritis</li> <li>Non-Hodgkin's lymphoma</li> <li>Chronic lymphocytic leukemia</li> <li>Granulomatosis with polyangiitis (Wegener's granulomatosis)</li> <li>Microscopic polyangiitis</li> </ul>
rituximab-arrx	<b>Riabni</b>	Amgen	soln for IV infusion	<ul style="list-style-type: none"> <li>Non-Hodgkin's lymphoma</li> <li>Chronic lymphocytic leukemia</li> <li>Granulomatosis with polyangiitis (Wegener's granulomatosis)</li> <li>Microscopic polyangiitis</li> </ul>
rituximab-pvvr	<b>Ruxience</b>	Pfizer	soln for IV infusion	<ul style="list-style-type: none"> <li>Rheumatoid arthritis</li> <li>Non-Hodgkin's lymphoma</li> <li>Chronic lymphocytic leukemia</li> <li>Granulomatosis with polyangiitis (Wegener's granulomatosis)</li> <li>Microscopic polyangiitis</li> </ul>

### NOTES

\*Drug is currently pending for launch. Please contact company for estimated availability dates or for more information.

<sup>†</sup>See drug monographs or full labeling for detailed description of indications.

Not an inclusive list of medications. Please see drug monograph at [www.eMPR.com](http://www.eMPR.com) and/or contact company for full drug labeling.